Phase 3 Trial Planned for Cabozantinib Plus Nivolumab-Ipilimumab in RCC
A double-blind, placebo-controlled phase 3 trial is planned to evaluate cabozantinib plus nivolumab and ipilimumab as first-line treatment for advanced clear cell RCC..
Kidney Cancer
Phase 3 Study to Evaluate HIF-2α Inhibitor in RCC
A phase 3, randomized, active-controlled trial will evaluate the efficacy and safety of a HIF-2α inhibitor for the second-line treatment of clear cell RCC.
Modified Nivolumab-Ipilimumab Dosing Shows No Benefit in Advanced RCC
A modified dosing regimen of nivolumab-ipilimumab for patients with advanced RCC did not provide additional benefit compared with standard dosing.
Phase 2 Study Initiated for HIF-2α Agent in Relapsed/Refractory RCC
A phase 2 trial has been initiated to evaluate a HIF-2α inhibitor for the treatment of advanced RCC after progression with another therapy.
Phase 3 Trial of Nivolumab With or Without Ipilimumab for Localized RCC After Nephrectomy
A phase 3 randomized placebo-controlled trial is recruiting to evaluate nivolumab plus ipilimumab among patients with localized RCC at risk of relapse after nephrectomy.
No Benefit to Modified Dosing of Lenvatinib-Everolimus in Advanced RCC
Modified dosing of lenvatinib-everolimus did not improve tolerability and may have modestly decreased efficacy compared with standard dosing in advanced RCC.
Survival Differences With Tremelimumab According to RCC Histology
RCC histology was associated with survival after treatment with tremelimumab, according to results of a post hoc analysis of a pilot trial.
COVID-Related Surgical Delays May Be Acceptable for Some Patients With Localized RCC
Surgical delays due to COVID-19 may be safe for some patients with localized RCC, and are unlikely to compromise survival for some individuals.
Patient-Specific Characteristics and Costs Related to Oral Targeted Therapy in Metastatic RCC
Age, marital status, and geographic location tended to influence use of oral anticancer therapy in older patients with metastatic RCC.
Nivolumab Plus Cabozantinib Under Review for Renal Cell Carcinoma
The applications are supported by data from the CheckMate -9ER trial that compared nivolumab, a programmed death receptor-1 blocking antibody, plus cabozantinib, a tyrosine kinase inhibitor, to sunitinib.
-
Loading...
-
Loading...
Next post in Kidney Cancer
